These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. An MS patient loses trust when she finds out her doctor is paid by drug companies. Wolston M Health Aff (Millwood); 2011 Dec; 30(12):2449-52. PubMed ID: 22147873 [No Abstract] [Full Text] [Related]
24. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
25. Biogen, Serono squabble over MS market. Davidson S Nat Biotechnol; 2001 Aug; 19(8):696-7. PubMed ID: 11479543 [No Abstract] [Full Text] [Related]
26. Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy. Eggert M; Goertsches R; Seeck U; Dilk S; Neeck G; Zettl UK J Neurol Sci; 2008 Jan; 264(1-2):145-50. PubMed ID: 17889033 [TBL] [Abstract][Full Text] [Related]
27. Symptomatic therapy in multiple sclerosis: Big pharma should do more - NO. Hughes SE; Gray OM Mult Scler; 2015 Jul; 21(8):978-9. PubMed ID: 26084348 [No Abstract] [Full Text] [Related]
28. Balancing the benefits and risks of new drugs for MS. Lancet Neurol; 2011 Jun; 10(6):491. PubMed ID: 21601155 [No Abstract] [Full Text] [Related]
29. Cladribine as a therapeutic option in multiple sclerosis. Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757 [TBL] [Abstract][Full Text] [Related]
30. [Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials]. Jakab G Ideggyogy Sz; 2012 May; 65(5-6):207-8. PubMed ID: 22724290 [No Abstract] [Full Text] [Related]
31. Daclizumab treatment for multiple sclerosis. Kim SE Pharmacotherapy; 2009 Feb; 29(2):227-35. PubMed ID: 19170591 [TBL] [Abstract][Full Text] [Related]
32. Cladribine for multiple sclerosis: review and current status. Sipe JC Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330 [TBL] [Abstract][Full Text] [Related]
33. Oral immunosuppression for multiple sclerosis. Engel WK Lancet; 1992 Jan; 339(8784):64-5. PubMed ID: 1345992 [No Abstract] [Full Text] [Related]
34. Reducing clinical trial risk in multiple sclerosis. De Gasperis-Brigante CD; Parker JL; O'Connor PW; Bruno TR Mult Scler Relat Disord; 2016 Jan; 5():81-8. PubMed ID: 26856949 [TBL] [Abstract][Full Text] [Related]
36. Antihypertensive therapies. Smith RE; Ashiya M Nat Rev Drug Discov; 2007 Aug; 6(8):597-8. PubMed ID: 17821828 [No Abstract] [Full Text] [Related]
37. Mitoxantrone (Novantrone) in multiple sclerosis: new insights. Neuhaus O; Kieseier BC; Hartung HP Expert Rev Neurother; 2004 Jan; 4(1):17-26. PubMed ID: 15853611 [TBL] [Abstract][Full Text] [Related]
38. [Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Con]. Linker RA Nervenarzt; 2015 Apr; 86(4):492-4. PubMed ID: 25694252 [No Abstract] [Full Text] [Related]
39. [Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Pro]. Meuth SG Nervenarzt; 2015 Apr; 86(4):491. PubMed ID: 25694251 [No Abstract] [Full Text] [Related]
40. Trial watch: enzyme replacement success in Phase III trial for rare metabolic disorder. Crunkhorn S Nat Rev Drug Discov; 2013 Jan; 12(1):12. PubMed ID: 23274460 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]